← back to search

Steffen Weikert

St. Hedwig-Krankenhaus ·
Area of research
Pulmonary and Respiratory Medicine · Surgery
Research interest
Research interests include Renal cell carcinoma treatment, Bladder and Urothelial Cancer Treatments, Prostate Cancer Diagnosis and Treatment, and Epigenetics and DNA Methylation.
h-index
37
citations
4,830
works
159
NIH funding
primary concept
email

Recent publications

Long-Term Follow-Up of Peritoneal Interposition Flap in Symptomatic Lymphocele Reduction following Robot-Assisted Radical Prostatectomy: Insights from the PIANOFORTE Trial
Cancers 2024cited by 1position: middledoi
High BMI, Aggressive Tumours and Long Console Time Are Independent Predictive Factors for Symptomatic Lymphocele Formation after Robot-Assisted Radical Prostatectomy and Pelvic Lymph Node Dissection
Urologia Internationalis 2021cited by 19position: middledoi
A Randomized Phase IIa Trial with Temsirolimus versus Sunitinib in Advanced Non-Clear Cell Renal Cell Carcinoma: An Intergroup Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer Society
Oncology Research and Treatment 2020cited by 35position: middledoi
Obesity leads to a higher rate of positive surgical margins in the context of robot-assisted radical prostatectomy. Results of a prospective multicenter study
Editor-in-Chief s Voice List of Authors is an Important Element in a Scientific Publication 2020cited by 8position: middledoi
One‐carbon metabolism biomarkers and risk of urothelial cell carcinoma in the European prospective investigation into cancer and nutrition
International Journal of Cancer 2019cited by 7position: middledoi
Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic<i>TMPRSS2:ERG</i>fusion status
Human Molecular Genetics 2016cited by 12position: middledoi
Meat and fish consumption and the risk of renal cell carcinoma in the <scp>E</scp>uropean prospective investigation into cancer and nutrition
International Journal of Cancer 2014cited by 26position: middledoi
N-acetyltransferase 2 Phenotype, Occupation, and Bladder Cancer Risk: Results from the EPIC Cohort
Cancer Epidemiology Biomarkers & Prevention 2013cited by 34position: middledoi
Practical Management of Everolimus-Related Toxicities in Patients with Advanced Solid Tumors
Oncology Research and Treatment 2013cited by 34position: middledoi
Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma
European Journal of Cancer 2013cited by 20position: lastdoi
Interdisciplinary decision making in prostate cancer therapy – 5-years’ time trends at the Interdisciplinary Prostate Cancer Center (IPC) of the Charité Berlin
BMC Medical Informatics and Decision Making 2013cited by 9position: middledoi
Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma
European Journal of Cancer 2012cited by 54position: middledoi
Plasma carotenoids and vitamin C concentrations and risk of urothelial cell carcinoma in the European Prospective Investigation into Cancer and Nutrition
American Journal of Clinical Nutrition 2012cited by 48position: middledoi
Macronutrient intake and risk of urothelial cell carcinoma in the European prospective investigation into cancer and nutrition
International Journal of Cancer 2012cited by 35position: middledoi
Fruit and vegetable consumption and risk of aggressive and non-aggressive urothelial cell carcinomas in the European Prospective Investigation into Cancer and Nutrition
European Journal of Cancer 2012cited by 30position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Viktor Grünwald · Dana-Farber Cancer Institute4 papers (2012–2020)Johannes Bründl · University of Regensburg3 papers (2020–2024) · 3 papers (2020–2024)Christopher Goßler · University of Regensburg3 papers (2020–2024)Christian Gilfrich · University of Regensburg3 papers (2020–2024) · 3 papers (2020–2024) · 3 papers (2020–2024) · 3 papers (2020–2024)Maximilian Burger · University of Regensburg3 papers (2020–2024)Bernd Rosenhammer · University of Regensburg2 papers (2020–2021)Jonas Busch · Vivantes Klinikum2 papers (2012–2013)Johannes Breyer · University of Regensburg2 papers (2020–2021)Christoph Seidel · Medizinische Hochschule Hannover2 papers (2012–2013)Matthias May · Caritas-Krankenhaus St. Josef2 papers (2020–2024)Kurt Miller · Mayo Clinic2 papers (2013–2013)Marianne Pavel · Charité - Universitätsmedizin Berlin1 papers (2013–2013)Irena Goranova · Humboldt-Universität zu Berlin1 papers (2013–2013)Marc‐Oliver Grimm · Klinik und Poliklinik für Urologie1 papers (2020–2020) · 1 papers (2013–2013)Thomas Wiegel · Universität Ulm1 papers (2013–2013)